Karyopharm Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
KPTI$0.02-56.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(22,392) | $(23,462) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 3,007 | 3,560 |
| Depreciation | 12 | 78 |
| Amortization of debt issuance costs and discounts | 2,362 | 2,573 |
| Interest expense added to debt principal | 6,911 | — |
| Net amortization of premiums and discounts on investments | 2 | (236) |
| Change in fair value of embedded derivatives and common stock warrants | (16,481) | (19,972) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 2,821 | (4,477) |
| Inventory | 439 | (30) |
| Prepaid expenses and other assets | 659 | 1,960 |
| Operating lease right-of-use assets | 139 | 407 |
| Accounts payable | 276 | 765 |
| Accrued expenses and other liabilities | (257) | (412) |
| Operating lease liabilities | (226) | 262 |
| Net cash used in operating activities | (22,728) | (38,984) |
| Investing activities | ||
| Proceeds from maturities of investments | 3,200 | 15,288 |
| Net cash provided by investing activities | 3,200 | 15,288 |
| Financing activities | ||
| Proceeds from issuance of common stock under Open Market Sale Agreement | 20,233 | — |
| Proceeds from issuance of common stock and warrants in private placement offering | 30,000 | — |
| Payment of equity issuance costs | (431) | — |
| Net cash provided by financing activities | 49,802 | — |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 2 | 5 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 30,276 | (23,691) |
| Cash, cash equivalents and restricted cash at beginning of period | 60,891 | 62,814 |
| Cash, cash equivalents and restricted cash at end of period | $91,167 | $39,123 |
| Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $90,850 | $38,783 |
| Long-term restricted cash | 317 | 340 |
| Total cash, cash equivalents and restricted cash | $91,167 | $39,123 |
| Supplemental disclosures: | ||
| Cash paid for interest on deferred royalty obligation | $— | $2,122 |
| Cash paid for interest on convertible debt and term loan | $— | $5,135 |
| Equity issuance costs included in accounts payable and accrued expenses | $1,508 | $— |
| Cash paid for amounts included in the measurement of operating lease liabilities | $467 | $— |
| Debt issued for interest payments | $6,911 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.